Goodwin advised Exosome Diagnostics on its definitive agreement to be acquired by Bio-Techne Corporation for $250 million in cash plus contingent consideration of up to $325…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
